Prospectively collected frailty markers are associated with an incremental 1-year mortality risk after transcatheter aortic valve replacement (TAVR) compared with comorbidities alone. Whether information on frailty markers captured retrospectively in administrative billing data is similarly predictive of long-term mortality after TAVR is unknown. We sought to characterize the prognostic importance of frailty factors as identified in healthcare billing records in comparison to validated measures of frailty for the prediction of long-term mortality after TAVR.
S
evere calcific aortic valve stenosis is the most common cause of valve replacement in the elderly population in the United States. 1 Although surgical aortic valve replacement remains the preferred treatment for severe symptomatic aortic stenosis in patients at low surgical risk, current guidelines recommend transcatheter aortic valve replacement (TAVR) as an alternative treatment in patients at increased surgical risk based on several clinical trials showing equivalence or superiority to surgery for patients with extreme, high, and intermediate surgical risks. [2] [3] [4] [5] [6] [7] [8] Risk stratification before TAVR is important when selecting those patients who will most likely benefit from the procedure. To date, clinical risk prediction models of 1-year mortality after TAVR have been developed using traditional risk scoring systems. These include the Society for Thoracic Surgery Predicted Risk of Mortality score 9, 10 and the logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE), 11 as well as other individual clinical risk predictors. [12] [13] [14] [15] [16] Prior studies have suggested that measurement of frailty can enhance the prediction of mortality after TAVR. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] In addition, a relatively small, prospective study recently showed that adding frailty measurements to conventional risk scores improved the assessment of 1-year mortality risk after TAVR. 31 However, the assessment of frailty in clinical practice can be challenging, and these factors are commonly not collected in the nationwide registries, such as the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. In the absence of prospectively collected data, the ability to identify these factors in billing records may allow for enhanced mortality prediction. To test this, we evaluated hospitalizations of patients undergoing TAVR in a Medicare inpatient database to determine whether the incorporation of claims-based measures of frailty might augment mortality prediction compared with using comorbidities alone.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Study Population
The Centers for Medicare and Medicaid Services MedPAR files include administrative billing claims for all hospitalizations of Medicare fee-for-service beneficiaries and have been used to study national patterns of procedure utilization in the United States. [32] [33] [34] In the MedPAR database, hospitalizations of adult patients (≥18 years old) were included if they had at least 1 
Cardiac and Noncardiac Covariates and Procedural Risk Factors
A total of 34 cardiac and noncardiac covariates and procedural risk factors were initially defined as possible risk factors for allcause mortality after TAVR based on our clinical knowledge. Age, sex, race, chronic heart failure, smoking, peripheral vascular disease, diabetes mellitus, and a couple of well-known cardiac diseases were defined as cardiac risk factors. Other comorbidities, such chronic kidney, liver and obstructive pulmonary diseases, anemia, obesity, hypothyroidism, coagulopathy, and the Charlson comorbidity index, were defined as noncardiac risk factors. Procedural risk factors included emergency or urgent admission, transapical access, and preprocedural shock.
Frailty Index
There are several ways to measure claims-based frailty. 35, 36 In this study, the Johns Hopkins Claims-based Frailty Indicator, a previously developed and both internally and externally validated index, was used to identify frailty. [37] [38] [39] [40] This index includes 21 criteria identifiable in claims data, such as demographic variables and markers of physical and cognitive dysfunction, to identify patients meeting the Fried frailty phenotype. 41 This has been extensively validated and shown to predict poor health outcomes, including incidence of falls, worsening mobility, hospitalization, and death. Based on the Johns Hopkins Claimsbased Frailty Indicator algorithm, 37 a score cutoff of ≥0.12 was used to identify frail patients (Table I in the Data Supplement).
Some variables included in the John Hopkins Claims-based Frailty Indicator, such as age, sex, and Charlson comorbidity index, overlap with variables commonly used for risk adjustment in TAVR patients. To examine the prognostic importance of frailty variables often omitted from risk adjustment, we classified a subgroup of variables in the frailty indicator as nontraditional frailty markers. These included impaired mobility, depression, Parkinson disease, any type of arthritis, cognitive impairment, paranoia, chronic skin ulcer, pneumonia, skin and soft tissue infections, mycoses, gout or other crystal-induced arthropathies, falls, musculosketal problems, and urinary tract infection.
All covariates were ascertained using secondary diagnosis codes that were coded as present on admission during the index hospitalization, as well as from principal and secondary diagnosis codes from all hospitalizations in the year before
WHAT IS KNOWN
• Frailty and disability play a key role in the identification of older patients' potential for improvement after transcatheter aortic valve replacement.
WHAT THE STUDY ADDS
• Our findings show that the inclusion of frailty and disability markers as identified in Medicare beneficiaries significantly improved the prediction of long-term mortality.
• These claims-based risk factors may allow for enhanced mortality prediction in the absence of prospectively collected data.
the date of admission of the index hospitalization (Table II in the Data Supplement).
Outcomes
The primary outcome for this study was all-cause long-term mortality, determined through linkage of the MedPAR files to the Centers for Medicare and Medicaid Services denominator file which includes information on a patient's vital status. Time to death was calculated as the time between the date of procedure and date of death. Patients were censored if they were no longer enrolled in Medicare according to the denominator file as of December 31, 2015, which marked the end of the follow-up period. The study was approved by the institutional review board of Beth Israel Deaconess Medical Center with a waiver of informed consent for retrospective data analysis.
Statistical Analysis
Continuous variables are presented as means and SDs, and categorical variables are presented as counts and percentages. Covariates were compared between surviving and nonsurviving patients using χ 2 statistics and t tests. KaplanMeier plots were created to plot time to death with a 30-day landmark analysis, stratified by the number of nontraditional frailty markers included. The log-rank test was used to compare the survival distributions of each frailty scale.
Covariates with a P <0.1 in univariate Cox regression analysis were ultimately included in the model. Subsequently, nested multivariable Cox regression incorporating random hospital effects was performed using 4 sequential models to determine the incremental improvement in prediction of long-term mortality with the addition of 4 sets of covariates. The sequential models included variables associated with (1) cardiac risk factors, (2) noncardiac risk factors, (3) procedural risk factors, and (4) nontraditional frailty markers. Harrell's C statistic was used to assess model discrimination, and the improvement in discrimination with the addition of variables was assessed by the change in the C statistic and the DeLong test. 42 An integrated discrimination improvement test was used to assess discrimination improvement. 43 All statistical analyses were performed in STATA software, version 15.0 (Stata Corporation, College Station, TX) using a 2-tailed P value for significance of <0.05.
RESULTS
A total of 52 338 hospitalizations from 558 clinical sites involved receipt of TAVR during the study period. The baseline characteristics of patients are shown in Table 1 . A total of 27 147 (51.9%) were men, and the mean age was 82.4±8.0 years. There were 34 863 (66.6%) patients who were identified as frail. Musculoskeletal problems (15.5%) and arthritis (13.9%) were the most prevalent nontraditional frailty markers.
Mortality
In total, 14 174 (27.1%) patients died within the study period, with a mean follow-up time of 16 months. The all-cause mortality rate was 3.6% in hospital, 5 
Discrimination Improvement and Model Covariates
In nested models, the discrimination of the first model including only cardiac risk factors was 0.60 (95% CI, 0.59-60). The addition of noncardiac risk factors in the second model resulted in a C statistic of 0.65 (95% CI, 0.64-0.65; integrated discrimination improvement=0.032; P<0.001 compared with the first model). With the incorporation of additional procedural characteristics in the third model, the C statistic was 0.68 (95% CI, 0.67-0.68; integrated discrimination improvement=0.019; P<0.001 compared with the second model). Finally, the inclusion of nontraditional frailty markers resulted in a C statistic of 0.70 (95% CI, 0.69-0.70; integrated discrimination improvement=0.019; P<0.001 compared with third model). Comparisons of the C statistics using the DeLong test were statistically significant (P<0. Table 2 ).
The HRs for the final covariates, determined from nested Cox regression analysis, are presented in Table 3 . The covariates that were most strongly associated with increased long-term mortality were atrial fibrillation (HR: 1.394; 95% CI, 1. Table III in the Data Supplement, the claims-based pre- dictors of long-term mortality used in the current study are similar to those defined in clinical studies.
DISCUSSION
In the present study, we show that administrative codes can be used to identify cardiac and noncardiac risk factors, procedural characteristics, and markers of frailty which likely rendered TAVR patients at high surgical risk. The majority of TAVR patients in the database were frail, and the incorporation of these factors into statistical models improved the prediction of long-term mortality in patients undergoing TAVR when combined with traditional risk factors. Furthermore, our results demonstrate that the rate of long-term mortality after TAVR gradually increases with an increasing number of recorded nontraditional frailty markers. These findings illustrate the impact of frailty on outcomes for patients undergoing TAVR.
Impact of Frailty on Long-Term Mortality
There is a paucity of clinical studies for patients with structural heart disease which include an assessment of risk factors for frailty. For instance, the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry, the largest registry collecting patient characteristics and outcomes related to TAVR procedures in the United States, collects only a few frailty markers, such albumin, hemoglobin, and the 5-meter speed test. 44 However, it has been demonstrated that incorporating frailty improves the prediction of mortality after TAVR. Adding a frailty index improved the C statistic for discrimination of 1-year mortality of the Society for Thoracic Surgery Predicted Risk of Mortality score from 0.64 to 0.68 (P<0.001) and improved the discrimination of the logistic EuroSCORE from 0.67 to 0.72 (P<0.001). 31 Afilalo et al 19 reported that the average prevalence of frailty in the TAVR population, based on assessments using 7 separate frailty scales, was 54% (37%-74%). Despite both its commonality and its importance, frailty scales are infrequently collected in routine clinical care. 45 In the absence of prospectively collected data on frailty, we show that prognostic information can be identified in claims data. Furthermore, we showed that including claims-based frailty alongside traditional risk factors in statistical modeling significantly improved the discrimination of long-term mortality. However, in our landmark analysis, adding nontraditional frailty markers did not predict differences in perioperative mortality. These results suggest that the incorporation of frailty is more important for the prediction of longterm mortality than perioperative mortality. In addition, the improvement performance of adding frailty was similar in magnitude to adding procedural covariates which are well-known risk factors 10 in the TAVR population. We think that by merging claims-based frailty data with ongoing structural heart registries, we might enhance the ability to define patient risk and understand long-term outcomes, improve hospital benchmarking, and increase the completeness of data collection.
Predictors of All-Cause Mortality After TAVR
Predictive models for in-hospital and 30-day mortality have provided moderate discrimination in the Transcatheter Valve Therapy registry (C statistic: 0.67 in the training data set; 0.66 in the validation sample) 10 and the France-2 Registry (C statistic: 0.67 in the training sample; 0.59 in the validation sample). 16 The primary advantage of our analysis of MedPAR data is the inclusion of a large, generalized population with the ability to track mortality for the long term. Although we do not have all the necessary variables to calculate traditional surgical risk scores, such as the Society for Thoracic Surgery Predicted Risk of Mortality or logistic EuroSCORE, the final model derived from MedPAR data had reasonable discrimination (C statistic=0.70), and the claims-based predictors of long-term mortality used in the current study are similar to those defined in clinical studies (Table III in 
Limitations
There are several limitations to the present study. The indications and criteria for patient selection for TAVR are not available, and administrative coding may misclassify some comorbidities and complications compared with prospective collection using standard clinical trial definitions. In addition, because the study population was limited to Medicare beneficiaries, we did not have information on all patients <65 years of age who might have undergone TAVR in the United States, and those patients <65 years who were included in the study may not be representative of younger patients overall.
Conclusions
Our findings show that risk prediction models that include frailty as identified in claims data can be used to more accurately predict long-term mortality risk after TAVR. Linkage to claims data may allow enhanced mortality risk prediction for studies that do not collect information on frailty. 
